General discussion 9 295 90. Al-Aly ZA-O, Bowe B, Xie YA-O. Long COVID after breakthrough SARS-CoV-2 infection. (1546170X (Electronic)). 91. Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. eClinicalMedicine 2022; 53. 92. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine 2022; 28(11): 2398-405. 93. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet 2022; 399(10343): 2263-4. 94. Siméon de B, Albert Jan van H, Elizabeth NM, et al. Lower prevalence of Post-Covid-19 Condition following Omicron SARS-CoV-2 infection. medRxiv 2023: 2023.04.05.23288157. 95. COFFI. The Collaborative on Fatigue Following Infection (COFFI). Available at: https://www.cofficollaborative.com/. Accessed 29 May. 96. Control ECfDPa. Outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): increased transmission beyond China − fourth update. Stockholm: ECDC, 14 February 2020. 97. Hooiveld M. Kennis voor betere zorg. Available at: https://www.nivel.nl/nl/nivel-zorgregistratieseerste-lijn/actuele-weekcijfers-aandoeningen-surveillance/nivel-peilstations-detailcijfersaandoeningen. Accessed 11 January 2023. 98. Influenzanet. The project. Available at: https://influenzanet.info/project. Accessed 29 May. 99. McDonald SS, L.; Schipper, M.; Friesema, I.H.M.; van den Wijngaard, C.C.; Teirlinck, A.; Neppelenbroek, N.; van den Hof, S.; Wallinga, J.; van Hoek, A.J. Testing behaviour and positivity for SARS-CoV-2 infection: Insights from web-based participatory surveillance. Research Square 2021. 100. Henning KJ. Overview of Syndromic Surveillance: What is Syndromic Surveillance? MMWR Morb Mortal Wkly Rep 2004; 53: 5-11. 101. Benschop Kimberley SM, van der Avoort Harrie G, Jusic E, Vennema H, van Binnendijk R, Duizer E. Polio and Measles Down the Drain: Environmental Enterovirus Surveillance in the Netherlands, 2005 to 2015. Applied and Environmental Microbiology 2017; 83(13): e00558-17. 102. (RIVM) RvVeM. Toekomstige mogelijkheden voor rioolwateronderzoek. Available at: https:// www.rivm.nl/rioolwateronderzoek/toekomstige-mogelijkheden-voor-rioolwateronderzoek. Accessed 22 May. 103. Koopsen J vEC, Bavalia R, Cornelissen A, Bruisten SM, de Gee F, et al. Epidemiologic and Genomic Analysis of SARS-CoV-2 Delta Variant Superspreading Event in Nightclub, the Netherlands, June 2021. Emerg Infect Dis 2022; 28: 1012-6. 104. EU-Lex. Betere bescherming, nieuwe mogelijkheden - Richtsnoeren Commissie voor de directe toepassing van de algemene verordening gegevensbeschermnig met ingang van 25 mei 2018. Available at: https://eur-lex.europa.eu/legal-content/NL/TXT/?uri=COM:2018:43:FIN. Accessed 12 June. 105. Pottegård AA-O, Kristensen KB, Reilev M, et al. Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort. (1179-1349 (Print)). 106. Islamoska S, Petersen JH, Benfield T, Norredam M. Socioeconomic and demographic risk factors in COVID-19 hospitalisation among immigrants and ethnic minorities. Eur J Public Health 2022; 32(2): 302-10. 107. Coyer L, Boyd A, Schinkel J, et al. SARS-CoV-2 antibody prevalence and determinants of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June-October 2020. medRxiv 2021: 2021.03.08.21252788.
RkJQdWJsaXNoZXIy MTk4NDMw